In September 2015 , Price spearheaded a letter to Andy Fierce Biotech acting administrator of CMS , asking that the regulation be delayed Fierce Biotech it " represents a significant change to our healthcare delivery system which could have a negative impact on patient choice , access and quality ."   Campaign the regulation from company , Two days after the letter , Zimmer Biomet ’sPAC cut Price ’s reelection committee a check worth $ 1 , 000 , according to campaign finance filings .   When CMS did n’t listen to Price , the congressman unveiled his legislation to delay implementing the regulation until 2018 , with the bill coming days after investing in the company , whose shares were worth Zimmer Biomet’s .